Prescribing Isotretinoin for Transgender Patients
isotretinoin for transgender patients
by NEXT STEPS IN DERM TEAM on
Case Scenario A 26-year-old patient presents to the dermatology clinic with severe nodulocystic scarring acne. The patient identifies as a transgender male and notes that he has been receiving hormone replacement therapy for the past 4 years with weekly intramuscular testosterone injections. He has not had any gender-affirming surgeries and reports being currently amenorrhoeic. He is curren …
Recalcitrant Dyshidrotic Eczema Treated With Dupilumab
eczema
by NEXT STEPS IN DERM TEAM on
The following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens. Introduction Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c …
Tranexamic Acid to Prevent and Treat Post-Inflammatory Hyperpigmentation
Tranexamic Acid
by NEXT STEPS IN DERM TEAM on
ABSTRACT The risk of post-inflammatory hyperpigmentation (PIH) in patients undergoing dermatologic procedures is well known. It is especially common after laser procedures and chemical peels but can be seen with any procedure. PIH is also a sequela of acne, burns, and other trauma. High-risk patients are thought to have excessive production and abnormal distribution of melanin within the skin tha …
The Pinch Stitch: A Pearl for Suturing Wounds Under Tension
pinch stitch
by NEXT STEPS IN DERM TEAM on
Closing defects under tension in areas such as the scalp and back may be challenging during dermatologic surgery. Different techniques have been advocated to ease the placement of the first deep suture under tension, including the slip-knot stitch, pully stitch, horizontal mattress suture, pulley set-back dermal suture, and tandem pulley stitch. INTRODUCTION Closing defects under tension in …
Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab
Oral Mucositis
by NEXT STEPS IN DERM TEAM on
Treatment of malignancy with anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors can cause mucocutaneous side effects resulting from T cell activation. Due to their recent development, the full side effect profile remains to be fully elucidated, however dermatologic adverse events are most common. The main oral toxicities of these immune checkpoint inhibitors include: xerostomia, dysg …